$CTXR “StockWireNews” Promoter Rank: 32/33 Citius Pharmaceuticals Inc. Newsletter 7:33:13 AM July 7, 2020

on July 7, 2020 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "StockWireNews"

The following three charts can be used by potential investors to gauge the performance of "StockWireNews":

40%

2 out of 5 campaigns closed down on first day

60%

3 out of 5 campaigns closed up on first day

0%

0 out of 5 campaigns had no net effect

CTXR Promotional Newsletter

The following is a newsletter released by "StockWireNews" promoting Citius Pharmaceuticals Inc.

Caution

The following newsletter has not been verified for accuracy or completeness.

Drop what you're doing and get past champ NASDAQ profile Citius Pharmaceuticals, Inc. CTXR on your radar right now. Here's why... The

StockWireNews

Get Past Champ NASDAQ Idea CTXR Pulled Up Quickly Today

$7.00 Price Target -

Based On Several Potential Catalysts, CTXR Displays Staggering Upside Potential

July 7th

Good Morning,

Drop what you're doing and get past champ NASDAQ profile Citius Pharmaceuticals, Inc. CTXR on your radar right now. Here's why...

The last time I brought this profile to your attention which at the time CTXR looked undervalued, it opened at $.97 on June 3rd, 2020.

Within a few weeks, CTXR rocketed all the way to a high of $1.97 for an overall surge of approximately 103%.

Take a look for yourself

That happened in major part to a huge press release on the 26th. Check it out

Citius Receives FDA Response on Pre-Investigational New Drug PIND Application for its Induced Mesenchymal Stem Cells iMSCs to Treat Acute Respiratory Distress Syndrome ARDS in Patients with CV-19

- FDA provides very specific guidelines to study iPSC-derived MSCs

- Company intends to submit an IND application for its iMSC therapy for patients with ARDS associated with CV-19

CRANFORD, N.J., June 26, 2020 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq CTXR, a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration FDA in regards to its pre-investigational new drug PIND application for its induced mesenchymal stem cells iMSCs to treat and reduce the severity of acute respiratory distress syndrome ARDS in patients with CV-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control CMC requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug IND application under the C-virus Treatment Acceleration Program CTAP.

Myron Holubiak, Chief Executive Officer of Citius, commented, We appreciate the FDA's thoughtful guidance on our unique, allogeneic mesenchymal stem cells derived from induced pluripotent stem cells iPSCs. We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to CV-19.

-----

The World House has called on U.S. health regulators to expedite potential therapies aimed at treating CV-19 amid the fast-spreading CV outbreak, saying it could lead to a breakthrough while a vaccine is still under development.

Trials on potential CV therapies are already in the works, and FDA Commissioner Stephen Hahn said his agency was working quickly to examine all possibilities.

In the short term, we're looking at drugs that are already approved for other indications, Hahn said. Since this outbreak first emerged, we've been working closely with our partners across the U.S government and around the globe to expedite the development and availability of critical medical products to help end this outbreak as quickly as possible.

That's what makes new NASDAQ profile, Citius Pharmaceuticals, Inc. CTXR, such an exciting stock in the short-term.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products.

Potential CTXR Major Catalyst - Positive FDA Feedback

Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok Therapy

- Compatibility plan includes testing representative samples of all commercially available CVCs and PICCs

- Plan is designed to be conducted in parallel with the completion of the Phase 3 pivotal trial

- Targeted worldwide market for Mino-Lok is expected to reach $1.84Bn by 2028

CRANFORD, N.J., June 2, 2020 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq CTXR, a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has received positive feedback from the Food and Drug Administration FDA on its proposed catheter compatibility studies for the Company's Mino-Lok therapy. The studies, if and when successfully completed, should allow Mino-Lok to be labeled for use with all commercially available central venous catheters CVCs and peripherally inserted central catheters PICCs on the U.S. market. It is further assumed that these studies will meet European and world standards.

The ability to be labeled without restrictions with respect to catheter type would allow Mino-Lok unrestricted access to the full U.S. and world markets for an effective antibiotic lock therapy for central line-associated bloodstream infections CLABSIs, which are estimated to be over $1.5Bn per year worldwide. The catheter compatibility studies will be conducted in parallel with the completion of the ongoing Phase 3 clinical study. The Company announced in early February 2020 that this pivotal trial had reached the halfway point for enrollment. The next milestone in the trial is the result of an interim efficacy analysis, which is expected to occur in the second half of 2020.

We believe we continue to check all the boxes required for an NDA submission, commented Myron Holubiak, Chief Executive Officer of Citius. According to our planned dosing recommendations, the Mino-Lok solution dwells in the catheter for two hours per day for 5 to 7 days. This would be between 10 to 14 hours of aggregate, but intermittent, exposure time of the catheter to Mino-Lok. We believe that this exposure is far lower than what is recommended for home-brewed antibiotic lock solutions, which should lead to less intrusive therapy and fewer days on therapy for patients.

The shorter dwell time for Mino-Lok also means that the catheter is available for its intended purpose, allowing treatment for the underlying disease to continue. Additionally, and more importantly, our pivotal trial is designed to show the superiority of Mino-Lok to standard antibiotic locks in time-to-catheter-failure. If all these studies prove to be successful, we believe ready-to-use Mino-Lok will be superior to home-brewed antibiotic locks in both efficacy and dosing schedules, Mr. Holubiak concluded.

Mino-Lok is an antibiotic lock solution used to treat patients with CLABSIs and catheter-related bloodstream infections CRBSIs in combination with an appropriate systemic antibiotics to preserve central venous access and to avoid the complications and morbidities associated with catheter removal and reinsertion procedures. It has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected catheter. Each year, up to 500,000 CVCs of the 7 million used become infected and lead to CLABSIs, increasing both patient morbidity risk and costs to the medical system. It has been shown that antibiotics alone are unable to penetrate the biofilm caused by bacteria, and there are currently no approved therapies for salvaging infected central venous catheters. According to DelveInsight, the market size of CLABSIs and closely associated CRBSIs in the global market is expected to reach $1.84Bn in 2028, up from $1.24Bn in 2017.

Potential CTXR Major Catalyst - May's Shareholder Letter

Citius Pharmaceuticals Issues May 2020 Shareholder Letter

- Company highlights exclusive option to license novel stem-cell therapy for ARDS related to CV-19 from Novellus, Inc.

- Status of pivotal Ph. 3 trial evaluating Company's lead-product Mino-Lok as an antibiotic lock solution used to treat catheter-related bloodstream infections CRBSIs is emphasized

- Regulatory and clinical updates on Mino-Wrap and Halo-Lido also discussed

CRANFORD, N.J., May 12, 2020 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq CTXR, a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that the Company has issued its May 2020 Shareholder Letter. The letter highlights the Company's exclusive option to license a novel stem-cell therapy to treat acute respiratory distress syndrome ARDS associated with CV-19, and the clinical progress of the Company's core products Mino-Lok, Mino-Wrap, and Halo-Lido.

Recent Company Highlights include

Submitting a pre-IND to the FDA under the CV Treatment Acceleration Program CTAP for a novel stem-cell therapy to treat ARDS associated with CV-19
Obtaining an exclusive option from Novellus, Inc. to license a stem-cell therapy to treat ARDS associated with CV-19
Achieving 50% patient enrollment in the Phase 3 Mino-Lok pivotal trial
Passing the interim futility analysis successfully in the ongoing Phase 3 trial of Mino-Lok vs. standard-of-care antibiotic locks

Despite the challenges presented by CV-19, we are in the midst of an exciting time for Citius, said Myron Holubiak, Chief Executive Officer of Citius. We're hard at work on a potentially groundbreaking treatment for ARDS associated with CV-19, and our core therapies are making steady progress through their respective clinical development timelines. I look forward to sharing the future developments with our shareholders as we move forward with our pipeline and achieve clinical and regulatory milestones.

-----

Potential CTXR Major Catalyst - $7 Dawson James Price Target

Here are some of the highlights from the Dawson James Securities updated October 2019 analyst report

First Interim Reached Citius announced that the first interim analysis point 37 catheter failures, which represents 40% of the anticipated events at 58 patients has been reached. The DSMB will now review the data and come back with analysis in about six weeks. We see the most likely recommendation being that the trial continues, unchanged. The DSMB could recommend increasing the trial add statistical power to see the signal with a p-value. The trial is designed with 80% power for an assumed 17 day difference between active and standard of care SOC. We typically expect the SOC arm to fail in 5-14 days.

Second Interim Analysis Superiority. At 69 events, or 75% of the total events anticipated at 108 patients, the DSMB will again review the trial. In this second analysis efficacy will be evaluated.

The FDA says Go For it. The FDA responded to the Company's proposal to refine the endpoints in the current Phase 3 pivotal trial for Mino-Lok. As a reminder, the current Phase 3 trial being conducted compares Mino-Lok therapy MLT to the standard of care, which is antibiotic lock therapy ALT. This is used to disinfect colonized catheters causing bacteremia and keep the treated catheters functioning and infection-free for eight weeks post-therapy.

New Endpoint Saves Time and Money. The new proposed primary endpoint is planned to demonstrate a significant difference in the time to catheter failure when comparing MLT to ALT. This is clinically important because eliminating the source of infection enables antibiotic treatment of the bacteremia to work more effectively and expeditiously. Additionally, if a catheter can be maintained for the time that it is needed, the patient does not need to be subjected to the procedures for removing and replacing the catheter that are associated with some serious adverse events. Citius believes that the change to the primary endpoint will result in fewer than 150 total subjects in Phase 3 trial and significant cost savings up to $10M.

Valuation. Our valuation is based on our therapeutic models and associated assumptions projected to 2030. Our model assumes multiple financial raises, and as such, our share count is based on a fully diluted out year basis. The lead product, MiniLok, is now in a Phase 3 trial. As such, we assume a 70% probability of success in our models. On top of this, we also use a 30% risk rate in our free cash flow to the firm FCFF, our discounted EPS dEPS and sum-of-the-parts SOP models. We equal weight and average these metrics and then round to the nearest whole number to derive our $7.00 price target.

-----

Potential CTXR Major Catalyst - H.C. Wainwright $4 Target

Back On January 24th, H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals to $4.00 from $1.65 while maintaining a Buy rating.

When you combine both the , you get a weighted average target of $5.50.

From CTXR's current trading levels Monday's close $1.35, that gives the stock approximately 307% potential upside.

-----

If there are any more updates, I'll get them out to you quickly today.

Sincerely,

Kai Parker

StockWireNews

Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.

Disclosure I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website andor reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.netdisclosure Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Stock Wire News stock wire news . com is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com SCF, an interest in the limited liability company that owns and operates fierce investor . com FI, and an interest in the limited liability company that owns and operates stock street wire . com SSW. From time to time, Stock Wire News, SCF, FI andor SSW publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews was hired for a period beginning on 72619 and ending on 72919 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 9319 and ending on 9419 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 121819 and ending on 121919 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 2420 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 31120 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 4220 and ending on 4320 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid twenty-five thousand five hundred USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 42820 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 51320 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 6220 and ending on 6320 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of CTXR. To date, we have now been compensated one hundred and sixty-five thousand five hundred USD via bank wire transfer to disseminate information about CTXR. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 7720 and ending on 7820 to publicly disseminate information about CTXR via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of CTXR. To date, we have now been compensated one hundred and ninety-three thousand USD via bank wire transfer to disseminate information about CTXR.

Stock Wire News 99 Wall Street Unit 883 New York, New York 10005 United States

Last 2 Stock Promotions By "StockWireNews"

Symbol Company Start Date Close Change
EVAHF EGF THERAMED HEALTH CORP. June 19, 2020 0.561 17%
ODYY Odyssey Group Intl Inc. June 17, 2020 0.800 7%